Call for Abstracts

June 3-7, 2011 | McCormick Place | Chicago, Illinois

SUBMISSION DEADLINE: February 2, 2011, 11:59 PM (EASTERN STANDARD TIME)
## ANNUAL MEETING AND ABSTRACT SUBMISSION KEY DATES


<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 29, 2010</td>
<td>Registration and Housing open exclusively for ASCO members.</td>
</tr>
<tr>
<td>November 15, 2010</td>
<td>Abstract Submitter opens.</td>
</tr>
<tr>
<td>December 1, 2010</td>
<td>General Registration and Housing open.</td>
</tr>
<tr>
<td>March 14-15, 2011</td>
<td>The Scientific Program Committee meets to select abstracts.</td>
</tr>
<tr>
<td>Late March 2011</td>
<td>Abstract notification letters are sent by e-mail to First Authors regarding the decisions of the Scientific Program Committee.</td>
</tr>
<tr>
<td>April 1, 2011</td>
<td>Deadline for submission of updated Late-breaking Abstracts.</td>
</tr>
<tr>
<td>Mid-April 2011</td>
<td>First Authors of Late-breaking Abstracts are notified of final decisions regarding selection of abstracts.</td>
</tr>
<tr>
<td>April 15, 2011</td>
<td>Deadline to withdraw or make changes to an abstract.</td>
</tr>
<tr>
<td>April 18, 2011</td>
<td>The online Annual Meeting Planner, which offers express or customized meeting itineraries, is available at chicago2011.asco.org.</td>
</tr>
<tr>
<td>May 18, 2011</td>
<td>Abstracts released on ASCO.org.*</td>
</tr>
<tr>
<td>June 3-7, 2011</td>
<td>47th ASCO Annual Meeting at McCormick Place, Chicago, Illinois.</td>
</tr>
</tbody>
</table>

* Full-text versions of Plenary, Late-breaking, and Clinical Review Abstracts will be publicly released during the Annual Meeting.
ASCO is now accepting abstracts to be considered for presentation or publication at the 47th Annual Meeting, June 3-7, 2011, in Chicago, Illinois. This year’s meeting will focus on Patients, Pathways, and Progress and will provide an opportunity to discuss the latest innovations in research, quality, and practice in cancer.

To submit your original research abstract of 300 to 350 words, visit the Call for Abstracts section of ASCO’s Annual Meeting website, www.asco.org/cfa. There you’ll also find detailed information on Annual Meeting abstract policies, submission requirements, and the abstract selection process, as well as Coauthor Disclosure Forms and Frequently Asked Questions.


“Abstracts presented at the ASCO Annual Meeting reach a worldwide audience of practicing oncology professionals, researchers, and patient advocates. There is no larger stage on which to share your work, gather critical feedback, and develop new collaborations.”

—Kathy Miller, MD
Indiana University Simon Cancer Center, and 2010-2011 Scientific Program Committee Chair
ABSTRACT POLICIES

Upon submission of an abstract to the ASCO Annual Meeting, the First Author must agree to the following Confidentiality Policy on behalf of all parties involved with the abstract. The First Author is also responsible for communicating this policy to all involved parties.

CONFIDENTIALITY POLICY

Abstracts submitted to the Annual Meeting are considered confidential from the time of submission. Prior to the information being publicly released in conjunction with the Annual Meeting, the author, coauthors, sponsor of the research, journalists, and others may not
1. make the information public, or provide it to others who may make it public (such as news media),
2. publish or present the information or provide it to others who may publish or present it,
3. use the information for trading in the securities of any issuer, or provide it to others who may use it for securities trading purposes.

For a study to be eligible for acceptance into the Annual Meeting, information contained in the abstract, as well as additional data and information to be presented about the study at the Annual Meeting, must not be disclosed before the findings have been publicly released in conjunction with the Annual Meeting. If information from the abstract or additional study data are disclosed in advance of public release in conjunction with the Annual Meeting, the abstract will no longer be eligible for inclusion in the Annual Meeting, or will be subject to removal from the Annual Meeting, unless an official Confidentiality Policy Exception applies (see below).

Furthermore, the contents and conclusions of the abstract must not be presented at any scientific, medical, or educational meeting of 500 registrants or more or be published in a scientific, medical, or educational publication (in any medium), in whole or in part, before the Annual Meeting. ASCO-cosponsored meetings represent an exception to this restriction on prior presentation and publication. Studies submitted to the Gastrointestinal Cancers Symposium, Genitourinary Cancers Symposium, Breast Cancer Symposium, Annual Meeting on Molecular Markers in Cancer, and other ASCO-cosponsored meetings where ASCO is the lead sponsor are eligible for acceptance even if previously presented or published in the scientific, medical, or educational arena. Abstracts presented at these particular ASCO meetings may also be submitted for presentation at any other ASCO meeting. Authors are encouraged to provide updated data in the abstract, as the novelty of the data will be taken into account during the abstract selection process.

CONFIDENTIALITY POLICY EXCEPTION

A Securities and Exchange Commission (SEC) Exception applies to the extent necessary to comply with securities laws. Guidance on the SEC Exception is available from ASCO. Other Abstract Exceptions to the Confidentiality Policy may be granted by ASCO in rare circumstances for public health reasons or to meet requirements of a government agency. Requests for public health or government agency exceptions should be directed to ASCO. Confidentiality Policy Exceptions for prior publication or prior presentation are rarely granted, but requests should be directed to ASCO as well.

Even if a Confidentiality Policy Exception applies or is granted, ASCO retains the right, in its discretion, to change the abstract’s placement in the meeting based on the extent of information disclosed. If an exception applies or is granted, the study generally will not be eligible for inclusion in the official press program for the Annual Meeting.
CONFLICT OF INTEREST POLICY AND EXCEPTIONS

In compliance with standards established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006; 24[3]:519-521) and the Accreditation Council for Continuing Medical Information (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the Society’s Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006;24[3]:520).

The ASCO Conflict of Interest Policy requirements apply to all abstract authors. It is the responsibility of the First Author to obtain disclosure information from all coauthors and to provide all disclosure of such interests and relationships through the Abstract Submitter program. Copies of the Disclosure Forms (which can be downloaded at www.asco.org/cfa) can be sent to coauthors for completion and return before submission of the abstract.

Per the ASCO Conflict of Interest Policy Implementation Plan for CME Activities, all Oral Abstract Presenters will be subject to the same disclosure review and management strategies as faculty who participate in ASCO CME activities.

For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract may be ineligible for placement in the 2011 Annual Meeting unless the Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

When a principal investigator has restricted relationships, the First Author will be prompted to apply to the Ethics Committee for an exception to the Policy. ASCO will collect information on accrual initiation date, financial relationships of the principal investigator, and National Institutes of Health (NIH) funding upon abstract submission. NIH-funded trials are exempt from the Policy restrictions.

Exception request materials may be uploaded as part of the abstract submission process or e-mailed to coi@asco.org. The final deadline for submission of exception request materials is February 2, 2011.

For more information on the ASCO Conflict of Interest Policy, the Conflict of Interest Policy Implementation Plan for CME Activities, the restrictions on principal investigators, and applying for an exception to the Policy, please visit www.asco.org/conflictofinterest.

ADDITIONAL QUESTIONS FOR CLINICAL TRIAL ABSTRACTS THAT DO NOT IDENTIFY A PRINCIPAL INVESTIGATOR

ASCO's Conflict of Interest Policy identifies the principal investigator (PI) of a clinical trial as "the individual with primary responsibility for the development of the protocol, the conduct of the trial, and the interpretation and dissemination of the trial data." Generally, it is expected that these responsibilities will rest with a single individual designated as the principal investigator and having the unique leadership responsibilities described in the Policy.

Identifying a PI is not required for abstract submission. However, First Authors of clinical trial abstracts that do not identify a PI will be asked to respond to additional questions about the individual(s) who completed the responsibilities assigned to the PI under ASCO’s Conflict of Interest Policy.

PHIL MCARTEN

CHRIS SALATA
ABSTRACT PREPARATION AND SUBMISSION

ABSTRACT SUBMISSION CHECKLIST

During the submission process, please keep in mind the following requirements:

☑️ No more than 20 individual authors may be listed for each abstract. An authoring group may also be included.

☑️ E-mail addresses are required for all coauthors, as well as for the First Author. A search feature will be provided to find e-mail addresses for ASCO members. Any changes to member information can be made by visiting the MyASCO section of ASCO.org or by contacting ASCO Member Services at 888-282-2552, 703-299-0158, or via e-mail at membermail@asco.org. Please note that member information cannot be updated within the Abstract Submitter.

☑️ Conflict of interest disclosure information must be submitted for the First Author and for all coauthors. Coauthor Disclosure Forms can be downloaded at www.asco.org/cfa. Note that there is a separate form for abstracts that report on clinical trials.

☑️ Submissions must adhere to the biostatistical guidelines (see www.asco.org/cfa) set forth by the Biostatics Core of the Scientific Program Committee. Although all of the elements are not required, the absence of one of more elements may have a negative effect on the abstract review and placement process.

☑️ Abstracts may not exceed 2,000 characters (approximately 300 to 350 words). This includes characters used in an abstract title and table, but does NOT include spaces or author names and institutions.

☑️ The title should objectively describe the study. Do not refer to study results or conclusions in the title. ASCO reserves the right to edit conclusive titles.

☑️ Do not use proprietary names in the title or body of the abstract. (If necessary, you may include a proprietary name in parentheses directly after the generic name on first use in the body of the abstract.) ASCO reserves the right to replace proprietary names with generic names.

☑️ A $60 administrative fee will be charged per abstract submitted. Credit cards will be the only acceptable form of electronic payment.

☑️ Abstracts may include one data table. Figures or images should not be included.

For more detailed information on these requirements and for additional abstract submission guidelines, visit www.asco.org/cfa.
WHAT’S NEW IN 2011?

Twenty (20) individual authors who meet the definition of authorship as stated by the International Committee of Medical Journal Editors may be listed for each submitted abstract. The First Author will appear in the printed Annual Meeting Proceedings; the full author block will be published in the online abstract and in the Annual Meeting Program. One authoring group may also be included along with the individual author names.

RESPONSIBILITIES OF THE FIRST AUTHOR

The First Author may submit only ONE abstract as First Author (unless submitting to the Trials in Progress Poster Session; see page 8 for more information).

THE FIRST AUTHOR MUST

- Obtain sponsorship from an ASCO Active or Active-Junior member, if he or she is not an ASCO member. An ASCO Active-Allied member, Associate member, or International Corresponding member may sponsor his or her own abstract but cannot sponsor an abstract for another First Author. An ASCO Affiliate member must obtain sponsorship.
- Verify that, if necessary for the work reported, the clinical research represented in the abstract was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.
- Verify that all coauthors are aware of the contents of the abstract and support its data.
- Agree, on behalf of all coauthors, to transfer copyright to ASCO.
- Agree to present the abstract if it is selected for presentation at the ASCO Annual Meeting. (This includes being present during the scheduled time of a Poster Session.) If the first author is employed by a commercial interest as defined by the Accreditation Council for Continuing Medical Education, and the content relates to the products or business lines of the employer, an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an Oral Abstract Session.
- Adhere to the ASCO Conflict of Interest Policy (J Clin Oncol. 2006;24[3]:519–521) and obtain disclosure information from all coauthors using the appropriate disclosure forms (forms can be downloaded at www.asco.org/cfa).
- Comply with ASCO’s conflict of interest management decisions, including the potential for slide review prior to presentation (Oral Abstract Presenters only). Information on these procedures is available at www.asco.org/conflictofinterest.
- Ensure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors (www.icmje.org/ethical_1author.html).
- Convey the Confidentiality Policy (see page 4) to all coauthors and the Sponsor(s) of the research.
- Enter the name of the clinical trial registry and the trial registration number if the abstract reports on a registered clinical trial.

RESPONSIBILITIES OF THE SPONSOR

An ASCO Active or Active-Junior member may sponsor multiple abstracts; otherwise, a Sponsor may sponsor only his or her own abstract.

THE SPONSOR MUST

- Be an ASCO Active, Active-Junior, Active-Allied or International Corresponding,1 or Associate member2 in good standing3
- Verify the contents of the abstract and support its data
- Comply with the Confidentiality Policy (page 4)

1 An ASCO Active-Allied or International Corresponding member may only sponsor his or her own abstract.
2 An ASCO Associate member who sponsors his or her own abstract must also obtain a signature from the Training Program Director. (The Training Program Director does not have to be an ASCO member and may sign for more than one Associate member.)
3 ASCO members who need to pay their membership dues should visit the MyASCO section of ASCO.org. Members who need to reactivate their membership should contact ASCO Member Services at 888-282-2552 or 703-299-0158.
ABSTRACT SELECTION PROCESS

Abstracts of superior quality will be selected by the ASCO Scientific Program Committee for presentation at the 2011 ASCO Annual Meeting and for publication in the 2011 ASCO Annual Meeting Proceedings, a supplement to the Journal of Clinical Oncology.

The Biostatistics Core of the Scientific Program Committee will conduct formal statistical review of all abstracts representing phase III trials and of other abstracts as determined by Program Committee Tracks. A member of the Biostatistics Core will be a voting member of each Committee Track, and his or her recommendations regarding the statistical validity of the abstract and its conclusions will influence the selection decisions. Failure to follow the biostatistical guidelines (which can be found at www.asco.org/cfa) will have a negative impact on the grading of the abstract by the Scientific Program Committee, decreasing the likelihood of presentation at the Annual Meeting.

Each First Author will receive a letter of notification via e-mail from the Committee regarding its decision on the abstract in late March. Each First Author of a Late-breaking Abstract will receive a letter of notification regarding the final decision in mid-April.

Abstracts will be judged solely on the data submitted. Statements such as “further data will be presented” are strongly discouraged and will decrease the likelihood that the abstract will be selected for presentation at the Annual Meeting. Additional appendices, illustrations, or other supplementary materials will not be accepted. Submission of one data table is permitted.

TOPIC CATEGORIES FOR ABSTRACT SUBMISSION

Authors must select one topic category that best fits the subject of their abstract. The 2010-2011 Scientific Program Committee reserves the right to recategorize an abstract.

- Breast Cancer—HER2/ER
- Triple-negative Breast Cancer/Cytotoxics/Local Therapy
- Cancer Prevention/Epidemiology
- Central Nervous System Tumors
- Developmental Therapeutics—Clinical Pharmacology and Immunotherapy
- Developmental Therapeutics—Experimental Therapeutics
- Gastrointestinal (Colorectal) Cancer
- Gastrointestinal (Noncolorectal) Cancer
- Genitourinary Cancer
- Gynecologic Cancer
- Head and Neck Cancer
- Health Services Research
- Leukemia, Myelodysplasia, and Transplantation
- Lung Cancer—Local-Regional and Adjuvant Therapy
- Lung Cancer—Metastatic Lung Cancer
- Lymphoma and Plasma Cell Disorders
- Melanoma/Skin Cancers
- Patient and Survivor Care
- Pediatric Oncology
- Sarcoma
- Tumor Biology
ONLINE-ONLY ABSTRACTS

Abstracts of acceptable quality that are not selected by the ASCO Scientific Program Committee for presentation may be chosen for inclusion online in the 2011 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology supplement. Online-only abstracts are publicly released at www.asco.org on May 18, 2011.

CHANGES TO ABSTRACTS

First Authors may request corrections to rectify errors (e.g., typos, misspellings) within abstract submissions. Requests for changes must be sent by the First Author to abstracts@asco.org. Updates to original data will not be permitted; changes are permissible only for the correction of errors. The deadline to submit change requests is April 15, 2011.

WITHDRAWAL OF ABSTRACTS

If the First Author wishes to withdraw his or her abstract for any reason, a request must be submitted via e-mail to abstracts@asco.org by April 15, 2011. Any abstract withdrawal request received after this date will be considered on a case-by-case basis and cannot be assured removal from the 2011 ASCO Annual Meeting Proceedings.
LATE-BREAKING ABSTRACTS

The ASCO Late-breaking Abstracts Policy allows for the submission of Late-breaking Abstracts only for phase III trials for which no preliminary data are available at the time of the abstract submission deadline (February 2), but for which a preplanned analysis of the primary endpoint is scheduled after that date but before April 1 (deadline for the final, updated Late-breaking Abstract). The policy is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the abstract submission deadline.

At the time of the Scientific Program Committee’s initial review of Late-breaking Abstracts (submitted by the February 2 deadline), two decisions are possible:
• Potential presentation in an Oral Abstract or Poster Discussion Session
• Rejection

At the time of the Committee’s review of updated Late-breaking Abstracts (after the April 1 deadline), three decisions are possible:
• Presentation in an Oral Abstract or Poster Discussion Session
• Online publication only in association with the content of the 2011 ASCO Annual Meeting Proceedings
• Rejection

Note that a decision regarding potential presentation does not guarantee that the abstract will be selected for presentation or publication after review of updated data. Final decisions regarding the selection of Late-breaking Abstracts will be made after April 1.

First Authors of Late-breaking Abstracts have an opportunity to request that the abstract be withdrawn if the Committee deems it acceptable for online publication only.

For Late-breaking Abstract submission guidelines, visit www.asco.org/cfa.

TRIALS IN PROGRESS POSTER SESSION

After a successful first year, the ASCO Annual Meeting will again include the Trials in Progress Poster Session, designed to facilitate awareness of open, ongoing clinical trials of any phase. This session will encourage discussions of new clinical research and the exchange of ideas on clinical trial design. Rather than a comprehensive review of all ongoing trials, the Trials in Progress Poster Session highlights the best and brightest ongoing clinical and translational research. No CME credit will be offered for this session.

Please note the following guidelines related to the Trials in Progress Poster Session:
• Abstracts submitted to the Trials in Progress Poster Session should not include results or conclusions.
• Trials in Progress abstracts will not count as the author’s one allowed submission.
• The administrative fee will apply to this abstract category.
• Sponsorship must be obtained from an ASCO Active or Active-Junior member, if the author is not an ASCO member.
• All conflict of interest policies apply.

For detailed submission guidelines, visit www.asco.org/cfa.

‘‘[The Trials in Progress Poster Session] is a novel idea that sparks collaborations and informs colleagues about trials.’’
—2010 Annual Meeting attendee
ABSTRACT-ASSOCIATED AWARDS

Trainees in the United States and other countries, as well as oncologists from countries with limited resources, are eligible for awards in conjunction with submitting an abstract for the Annual Meeting. These awards are offered through The ASCO Cancer Foundation® Grants Program.

MERIT AWARDS FOR FELLOWS AND JUNIOR FACULTY

A limited number of Merit Awards will be given to recognize trainees who submit high-quality abstracts. In addition to a $1500 stipend, the award includes complimentary registration for the Annual Meeting and access to Meeting housing reserved for ASCO members.

The First Author must meet all of the following requirements to be considered for a Merit Award:

• Hold a doctoral degree (including but not limited to MD, DO, PharmD, or PhD) or be a doctoral degree candidate at the time of abstract submission
• Be enrolled in an oncology fellowship training program or equivalent training program at the time of abstract submission
• Work in an oncology laboratory or clinical research setting
• Agree to present the abstract at the Annual Meeting
• Provide a letter of support from his or her Training Program Director, indicating eligibility for the award
• Provide a two-page curriculum vitae

INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD

The ASCO Cancer Foundation International Development and Education Award (IDEA) provides support for early-career oncologists in low- and middle-income countries to attend the ASCO Annual Meeting and to visit a cancer center in the United States or Canada. The IDEA program is designed to provide continuing medical education, assist in career development, and help recipients establish strong relationships with leading ASCO members who serve as scientific mentors. Submission of an abstract is a preferred, but not required, component of the application process.

In addition to the IDEA award, this year The ASCO Cancer Foundation is offering the IDEA in Palliative Care Award, a program with many of the same activities as the core IDEA award, but with a particular focus in palliative care. Recipients will have an opportunity to attend sessions at the Annual Meeting that address symptom management, communications, end-of-life care, and other relevant topics. They will be matched with leading ASCO members in the field of palliative care and will visit their mentor’s institution and experience palliative care performed in a multidisciplinary environment.

Award terms, eligibility requirements, and application information for both programs are available at www.ascocancerfoundation.org/idea.

Best of ASCO®

Annual Meeting ’11

CAN’T MAKE IT TO ANNUAL MEETING THIS YEAR?

Attend one of the official Best of ASCO® Meetings, where highlighted abstracts from the Annual Meeting are presented over two days. New in 2011, select educational sessions from the Annual Meeting will also be presented as part of an expanded Best of ASCO program. ASCO will offer two meetings in 2011. Choose from Best of ASCO Miami on July 29-30, 2011, at the Hyatt Regency Miami or Best of ASCO Seattle on August 5-6, 2011, at The Westin Seattle. Registration for the Best of ASCO Meetings opens in spring 2011.
SPONSOR YOUR OWN ABSTRACT AT THE 2011 ANNUAL MEETING

JOIN ASCO AND RECEIVE EXCLUSIVE MEMBERS ONLY BENEFITS

Interested in presenting your abstract at ASCO’s 2011 Annual Meeting, but not an ASCO member? All abstracts for the Annual Meeting must be sponsored by an ASCO member. Join today to submit and sponsor an abstract as first author and/or sponsor the work of your colleagues.*

Other meeting related benefits of ASCO membership:

- Save an average of 50%* off the Annual Meeting nonmember registration rates
- Receive advance access to hotels and sign up for the most sought-after ticketed sessions with Members Only Housing and Registration

JOIN TODAY to be part of the only professional organization that represents all oncology disciplines. Visit benefits.asco.org for a complete list of the benefits and resources ASCO provides and download a membership application. Simply submit your completed membership application to:

ASCO Member Services
2318 Mill Road, Suite 800 | Alexandria, VA 22314
Fax: (703) 299-0255 | E-mail: membermail@asco.org

For personal service, or to learn more about the benefits of ASCO membership, please call ASCO Member Services at (703) 299-0158 or (888) 282-2552.

* Varies by membership category